Dual CTLA‐4 and PD‐1 checkpoint blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors: A first‐in‐human, dose‐escalation, and dose‐expansion study.
Saved in:
| Title: | Dual CTLA‐4 and PD‐1 checkpoint blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors: A first‐in‐human, dose‐escalation, and dose‐expansion study. |
|---|---|
| Authors: | Bishnoi, Sarwan1,2 (AUTHOR) sbishnoi@adelaidecancercentre.com.au, Kotasek, Dusan1,2 (AUTHOR), Aghmesheh, Morteza3 (AUTHOR), Yau, Thomas4 (AUTHOR), Cosman, Rasha5 (AUTHOR), Prawira, Amy5 (AUTHOR), Moore, Maggie6 (AUTHOR), Chan, Stephen L.7 (AUTHOR), Mant, Andrew8 (AUTHOR), Eek, Richard9 (AUTHOR), Zielinski, Robert10 (AUTHOR), Su, Rila11 (AUTHOR), Pan, Zhaoxuan11 (AUTHOR), Ma, Yiding12 (AUTHOR), Li, Fei12 (AUTHOR), Li, Peiqi12 (AUTHOR), Tse, Archie N.11 (AUTHOR) |
| Source: | Cancer (0008543X). Jun2024, Vol. 130 Issue 11, p1991-2002. 12p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
